Fidelity Digital Health ETF

Resona Asset Management Reduces Stake in Intuitive Surgical by 13.1%

FAMAR Group Signs Contract Manufacturing Agreement with GE HealthCare to Expand Iodine Contrast Agent Capacity

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Dexcom Announces Launch of Dexcom Flex Continuous Glucose Monitoring System in Germany

GEHC Receives 'Hold' Consensus from 17 Brokers, Executives Buy Shares to Show Confidence

JD Health and AliHealth stocks fall on GLP-1 regulatory concerns, brokers call overreaction

Barclay's Analyst Matt Miksic Maintains Sell Rating on Dexcom with $64 Target

Dexcom Investor Day: Focus on G8 New Product, Doubling US CGM Coverage, and International Expansion Strategy

Wall Street Zen Upgrades Intuitive Surgical to Buy; Earnings and Revenue Beat Expectations

JD Health spends 8.9453 million HKD to repurchase 198,100 shares on May 15

Dexcom Announces 2030 Targets: 10% Revenue Growth and $10B Buyback

CSC Financial Maintains Buy Rating on JD Health International with Target Price of 58.28 HKD

Nomura lowers JD Health target price to HKD 67, maintains Buy rating

RBC Capital Analyst Maintains Hold Rating on Royal Philips with a Price Target of €25

GE HealthCare to Showcase AI-driven Radiotherapy Tools at ESTRO 2026

JD Health Authorized to Repurchase Up to $1 Billion in Shares

JD Health Reports Q1 2026 Revenue Growth of 17.0% to 19.468 Billion Yuan

ViCentra Launches Its New Kaleido Insulin Delivery Patch Pump System Commercially

GE HealthCare Director Receives Restricted Stock Units and Buys Stocks

Amesite

InMed Pharmaceuticals

Co-Diagnostics

Meiwu Tech

Phoenix Asia

Generation Income Properties

Rubico

MetaVia

Virax Biolabs

Agilysys

TDOC

HEAL

EDOC

FDHT

UBS analyst Kevin Caliendo has maintained a Hold rating on Teladoc (TDOC) with a price target of $6.00. Caliendo, a 4-star analyst, has an average return of 3.5% and a 53.71% success rate. Previously, Citi's Daniel Grosslight also issued a Hold rating, while Canaccord Genuity maintained a Buy rating on April 30.

Tip Ranks

Teladoc

Global X HealthTech ETF

Global X Telemedicine & Digital Health ETF

UBS Group AG

Dentsply Sirona

Cencora

Henry Schein

Citigroup

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Teladoc (TDOC) Gets a Hold from UBS

Shares of Teladoc Health (TDOC) rose over 4% on Friday, marking a seven-session winning streak and a total gain of approximately 22% since April 30. Despite a 38% increase over the past month, the stock is up only 2.7% year-to-date, lagging behind the S&P 500's 7% gain. Analysts highlight Teladoc's shift to a data-driven B2B healthcare model and improving financial metrics as positive indicators for future growth. Among 26 analysts, six rate the stock as a "strong buy," while one rates it as "buy" and 19 as "hold."

Teladoc Health extends rally to seventh straight session, gaining 22%

TD Cowen analyst Charles Rhyee has reaffirmed a Hold rating on Teladoc (TDOC) stock, citing tightened 2026 guidance for revenue and adjusted EBITDA margins. He projects adjusted EBITDA of $279 million for 2026 and $289 million for 2027, with Integrated Care contributing $251 million and BetterHelp $28 million. Rhyee maintains a $6 price target, indicating limited upside. Evercore ISI also holds a $6 price target on the stock, reflecting a neutral stance.

Evercore

Teladoc Hold Rating Reaffirmed as 2026 Outlook Tightens and $6 DCF-Based Price Target Remains Unchanged

Teladoc Health (NYSE:TDOC) reported Q1 2026 results with revenue of $614M and Adjusted EBITDA of $58M, exceeding guidance. CEO Chuck Divita highlighted a shift from subscription to visit-based care, which is seen as a near-term challenge but an opportunity for growth. Integrated Care revenue grew 1.5% to $395M, while BetterHelp revenue declined 9% to $218M. The company is investing in AI and expects to release new products later in 2026. Teladoc maintains its full-year outlook despite potential enrollment changes in health plans.

Market Beat

Peloton Interactive

Teladoc Health Q1 Earnings Call Highlights

Teladoc Inc. (TDOC) has maintained its risk disclosures in its latest Form 10-Q, indicating no material updates from its previous Form 10-K. This raises concerns about potential regulatory, competitive, operational, and macroeconomic pressures that could impact performance. The unchanged risk profile may suggest stability or a failure to recognize new threats, prompting increased scrutiny from investors. The average stock price target for TDOC is $7.16, indicating an 18.15% upside potential.

Unchanged Risk Disclosures at Teladoc Raise Questions About Emerging Threats and Investor Exposure

Earnings Snapshot: Teladoc Health issues weak Q2 revenue outlook after mixed Q1 results

businessinsider

Earnings Snapshot: Teladoc Health issues weak Q2 revenue outlook after mixed Q1 results

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

nasdaq

Nasdaq

Teladoc (TDOC) Q1 2026 Earnings Transcript

Teladoc Health (NYSE:TDOC) shares fell 5.6% to $5.62 after reporting mixed Q1 earnings. Revenue was $613.8 million, down 2% year-over-year, but above estimates. The company reported a net loss of 36 cents per share, missing expectations. Guidance for Q2 revenue is set between $597 million and $626 million, with a projected loss of 30 to 20 cents per share. For the full year, revenue guidance is narrowed to $2.481 billion to $2.576 billion, with an expected loss of $1.05 to $0.75 per share. CEO Chuck Divita emphasized a focus on strategic execution and long-term value.

benzinga_article

Teladoc Shares Fall After Q1 Earnings: What Investors Need To know

Teladoc Health is set to report earnings after market close on Wednesday. Last quarter, it reported revenues of $642.3 million, flat year-on-year, but missed revenue and EBITDA guidance for the next quarter. Analysts expect a 3% revenue decline this quarter. Despite missing estimates multiple times in the past two years, analysts have maintained their estimates. Teladoc's stock has risen 15.2% recently, with an average analyst price target of $7.09 against a current price of $5.92.

Stock Story

Coursera

Netflix

NVIDIA

NVIDIA Corporation

Teladoc (TDOC) Reports Earnings Tomorrow: What To Expect

BMED

The mHealth market worldwide is on the rise driven by various factors such as the growing acceptance of mHealth solutions, a rise in cases of heart disease, and an increased awareness about mHealth devices in developing nations. As of April 27, 2026, in Portland, Oregon, the market is gaining traction with significant numbers of users and patients turning to mHealth applications for healthcare needs.

Unusual Whales

Blackrock Future Health ETF

mHealth Market Size to Hit USD 370.7 billion, Globally, by 2032 at 18.0% CAGR: Allied Market Research

Fidelity Digital Health ETF(FDHT.US)

Teladoc (TDOC) Gets a Hold from UBS

Teladoc Health extends rally to seventh straight session, gaining 22%

Teladoc Hold Rating Reaffirmed as 2026 Outlook Tightens and $6 DCF-Based Price Target Remains Unchanged

Teladoc Health Q1 Earnings Call Highlights

Unchanged Risk Disclosures at Teladoc Raise Questions About Emerging Threats and Investor Exposure

Earnings Snapshot: Teladoc Health issues weak Q2 revenue outlook after mixed Q1 results

Teladoc (TDOC) Q1 2026 Earnings Transcript

Teladoc Shares Fall After Q1 Earnings: What Investors Need To know

Teladoc (TDOC) Reports Earnings Tomorrow: What To Expect

mHealth Market Size to Hit USD 370.7 billion, Globally, by 2032 at 18.0% CAGR: Allied Market Research